NCT04253561 2026-03-16
IPATHER
SOLTI Breast Cancer Research Group
Phase 1 Completed
Clinical Trials
10 trialsNCT05471648 2023-01-26
A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers
EirGenix, Inc.
Phase 1 Completed
NCT03135171 2021-09-10
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT02605915 2020-02-05
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT02060253 2018-06-14
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01918254 2017-09-12
A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein
Hoffmann-La Roche
Phase 1 Completed
NCT02490475 2017-05-17
A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02494596 2015-11-10
A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02507375 2015-10-16
A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 1 Completed
NCT00027027 2015-07-27
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
Genentech, Inc.
Phase 1 Completed